MoneyWorks4Me

Jubilant Pharmova informs about USFDA communication

27 Aug 2022 Evaluate
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Jubilant Pharmova has informed that it enclosed a press release pertaining to receipt of Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the USFDA for radiopharmaceuticals manufacturing facility of subsidiary company Jubilant Draximage Inc., at Montreal Canada. 

The above information is a part of company’s filings submitted to BSE.
Peers
Company Name CMP
Sun Pharma. Inds. 1835.50
Dr. Reddys Labs. 1171.10
Cipla 1371.45
Lupin 2144.70
Zydus Lifesciences 1153.00
View more..